Core Insights - Vanda Pharmaceuticals reported a strong financial performance for the full year 2025, with total revenues increasing by 9% to $216.1 million compared to 2024, driven primarily by a 24% increase in net product sales of Fanapt® [1][2] - The company is awaiting FDA approval for Bysanti™ (milsaperidone) for bipolar I disorder and schizophrenia, with a target action date of February 21, 2026, which could expand its psychiatry franchise [1][2] - The FDA approved NEREUS™ (tradipitant) for the prevention of motion-induced vomiting, marking a significant milestone as the first new oral therapy for this condition in over 40 years [1][2] Financial Highlights - For Q4 2025, Vanda reported a net loss of $141.2 million, compared to a net loss of $4.9 million in Q4 2024, with a diluted net loss per share of $2.39 [2][4] - The provision for income taxes in Q4 2025 was $103.2 million, influenced by a non-cash charge of $113.7 million against deferred tax assets [1][2] - Full year 2025 net loss was $220.5 million, compared to $18.9 million in 2024, with a diluted net loss per share of $3.74 [2][4] Operational Highlights - Fanapt® saw a 24% increase in net product sales for the full year 2025, totaling $117.3 million, supported by a 28% rise in total prescriptions [1][2] - The company launched a direct-to-consumer campaign in 2025, enhancing brand awareness for Fanapt® and PONVORY® [1][2] - Vanda is preparing for the commercial launch of NEREUS™ and plans to initiate a Phase III program for its use in preventing vomiting from GLP-1 analogs in the first half of 2026 [1][2] Regulatory & Clinical Development - Vanda received a decision letter from the FDA regarding the sNDA for HETLIOZ® for jet lag disorder, indicating it cannot be approved in its current form [2] - Ongoing clinical studies include a Phase III study of the long-acting injectable formulation of iloperidone for schizophrenia and a Phase III study of VQW-765 for social anxiety disorder [2] - The company submitted a BLA for imsidolimab for generalized pustular psoriasis in Q4 2025 [2] 2026 Financial Guidance - Vanda expects total revenues for 2026 to be between $230 million and $260 million, with Fanapt® net product sales projected to be between $150 million and $170 million [2]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices by Vanda Pharmaceuticals Inc. and its officers or directors, following a negative FDA decision regarding the approval of HETLIOZ for jet lag disorder [1][3]. Group 1: FDA Decision and Market Reaction - On January 8, 2026, Vanda announced that the FDA concluded the supplemental New Drug Application for HETLIOZ could not be approved in its current form, despite acknowledging positive efficacy from clinical trials [3]. - The FDA's decision was based on the view that the clinical trial protocols did not adequately simulate actual jet travel conditions, which involve additional factors such as reduced oxygen pressure and environmental changes [3]. - Following the announcement, Vanda's stock price dropped by $1.20 per share, a decline of 14.05%, closing at $7.34 per share on the same day [3]. Group 2: Legal Investigation - Pomerantz LLP is actively investigating claims on behalf of Vanda's investors, suggesting potential legal action related to the company's business practices [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2][6]. Group 3: Pomerantz LLP Overview - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of recovering significant damages for victims of securities fraud and corporate misconduct [4]. - The firm has been involved in the field of securities class actions for over 85 years, continuing the legacy of its founder, Abraham L. Pomerantz [4].

Core Viewpoint - Vanda Pharmaceuticals Inc. is under investigation for potential violations of federal securities laws following a significant stock price drop due to FDA's decision on its drug application for HETLIOZ® [1][2]. Group 1: Company News - Vanda Pharmaceuticals announced on January 8, 2026, that the FDA's CDER concluded that the supplemental New Drug Application (sNDA) for HETLIOZ® for treating jet lag disorder cannot be approved in its current form [2]. - The FDA acknowledged positive efficacy from Vanda's clinical trials but determined that the evidence was insufficient for effectiveness in treating jet lag disorder, citing that the trial protocols did not adequately simulate actual jet travel conditions [2]. - Following the FDA's announcement, Vanda's stock price fell over 14% on January 8, 2026 [2]. Group 2: Legal and Investigation - Levi & Korsinsky has commenced an investigation into Vanda Pharmaceuticals regarding potential violations of federal securities laws, inviting investors who suffered losses to explore recovery options [1][3].

Core Viewpoint - Vanda Pharmaceuticals Inc. is under investigation for potential securities fraud and unlawful business practices following the FDA's rejection of its supplemental New Drug Application for HETLIOZ® [1][3]. Group 1: FDA Decision - On January 8, 2026, Vanda announced that the FDA concluded the supplemental New Drug Application for HETLIOZ® for jet lag disorder cannot be approved in its current form [3]. - The FDA acknowledged positive efficacy from Vanda's clinical trials but determined that the data did not provide substantial evidence of effectiveness for jet lag disorder due to the inadequacy of the controlled phase advance protocols [3]. - Following the FDA's announcement, Vanda's stock price fell by $1.20 per share, or 14.05%, closing at $7.34 per share on January 8, 2026 [3]. Group 2: Legal Investigation - Pomerantz LLP is investigating claims on behalf of Vanda's investors regarding potential securities fraud or other unlawful business practices by the company and its officers and/or directors [1]. - Investors are encouraged to contact Pomerantz LLP for more information regarding the class action [2][6]. Group 3: Pomerantz LLP Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [4]. - The firm has a legacy of recovering multimillion-dollar damages awards for class members over its 85-year history [4].

Core Points - Vanda Pharmaceuticals Inc. achieved a significant legal victory against the FDA regarding the approval of HETLIOZ® (tasimelteon) for treating jet lag disorder [1][4] - The U.S. Court of Appeals for the D.C. Circuit ruled that the FDA must engage meaningfully with the evidence presented by drug innovators like Vanda [4][6] - The court's decision mandates that the FDA either approve the supplemental New Drug Application (sNDA) or conduct a hearing on the matter [4][6] Company Summary - Vanda submitted its sNDA in October 2018, but the FDA delayed the resolution, leading to a federal court ruling that the FDA violated the Food, Drug, and Cosmetic Act [2][3] - The court found that Vanda provided substantial evidence of tasimelteon's efficacy in improving sleep disturbances, with trials showing statistically significant improvements [4][5] - Vanda has invested over a decade in clinical studies to develop HETLIOZ®, which has the potential to significantly benefit individuals suffering from jet lag [5][6] Industry Impact - The court's ruling alters the relationship between the FDA and pharmaceutical companies, emphasizing the need for the FDA to fairly evaluate scientific evidence [6][7] - This decision may encourage other drug manufacturers to challenge FDA decisions that they believe are unjust, potentially leading to more innovative therapeutics reaching the market [7]